思城控股(01486.HK)附屬投資內地醫用放射性同位素項目 涉資2,500萬人幣
思城控股(01486.HK)公布,其全資附屬思城項目管理及非全資附屬邁達各斥2,000萬及500萬元人民幣(下同),認購元素投資發行的各1,999.64萬及499.91萬股,各持股36.37%及9.09%,且其他股東共出資3,000萬元。
各方出資金額合共約5,500萬元,將用於投資在中國註冊之合夥企業,後者擬投資於中國研發、轉化及生產醫用放射性同位素的投資項目;按不同階段劃分,投資項目總額約16億元。
公司指出,該投資項目的目標為填補中國醫用放射性同位素供應空白,透過建立整個醫用放射性同位素產業鏈,打破國內醫用同位素幾乎全部依賴進口的局面。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.